V
0.586
-0.02 (-3.14%)
| Previous Close | 0.605 |
| Open | 0.600 |
| Volume | 501,698 |
| Avg. Volume (3M) | 2,820,745 |
| Market Cap | 23,217,506 |
| Price / Sales | 173.92 |
| Price / Book | 1.95 |
| 52 Weeks Range | |
| Earnings Date | 12 Feb 2026 |
| Operating Margin (TTM) | 96,633.34% |
| Diluted EPS (TTM) | -1.67 |
| Quarterly Revenue Growth (YOY) | -43.10% |
| Total Debt/Equity (MRQ) | 2.14% |
| Current Ratio (MRQ) | 6.51 |
| Operating Cash Flow (TTM) | -42.10 M |
| Levered Free Cash Flow (TTM) | -23.27 M |
| Return on Assets (TTM) | -33.64% |
| Return on Equity (TTM) | -55.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | VistaGen Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
-0.5
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.50 |
|
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.35% |
| % Held by Institutions | 52.90% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Stempoint Capital Lp | 31 Dec 2025 | 616,749 |
| Luminus Management Llc | 31 Dec 2025 | 350,000 |
| 52 Weeks Range | ||
| Median | 0.900 (53.58%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 17 Dec 2025 | 0.900 (53.58%) | Hold | 0.860 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026 |
| 17 Dec 2025 | Announcement | Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |